engleski

Obesity treatment with Bioenterics intragastric balloon (BIB)

Aim of study: Assessment of the effectiveness, tolerance, safety and patients’ satisfaction treated for obesity with intragastric balloon. Methods: prospective controled trial of 35 obese patients treated with the BIB from March-December 2008. We analysed outcomes for 23 patients which completed 6 months treatment. All patients were included upon clinical workup of multidisciplinary team of experts (gastroenterologist, endocrinologist, psychiatrist). Results: 23 obese patients (18F, 5M) ; median age 34 years (range 20-58). Median baseline body weight (BW) was 114 kg (range 89-197) and body mass index (BMI) was 42.2kg/m2, range (31.2-60.8). Average weight reduction was 12kg (range 2-37), BW 10.1% (range 1.4-23.1), control BMI 36.3kg/m2 (range 29.4-50.3), delta BMI 4.5 (range 0.6-12.2). Excess weight (EW) before treatment 53kg (range 24-121), control EW 37kg (range 20-87), percentage excess weight loss (EWL) 23.8% (range 2.6-50.0). In one female patient (2.85%) intragastric balloon was early removed due to intolerance (nausea, vomiting, abdominal cramps). Minor sideeffects as nausea /vomiting during the first week in 16 patients (69.6%), occasional nausea/vomiting during first 3 week of treatment 3(13%), abdominal cramps during 1st week 10(43.5), oesophagitis 1(4.3%), hypokalemia 3(13%). There were no major complication as gastric ulcers/erosions, no acute renal failure and no need for surgical interventions. All intragastric balloons were sucessfully removed endoscopically. Patients’ treatment satisfaction correlated significantly to degree of BW loss (p= 0.0186). Conclusion: Our preliminary results showed that treatment with BIB is safe, well tolerated, with minor sideefects and alters for the better quality of life to patients. Complication rate in our series was neglectable, due to detailed pretreatment workup and follow-up.

BIB; bioenterics; intragastric balloon; obesity treatment; efficiency

nije evidentirano